FDA 483 Observations vs. Warning Letter
Article Context:
Companies in the life sciences, food, and cosmetics industries are all too aware of how fickle the market is, how dynamic their studies and those under investigation are, as well as their timelines for releasing a specific medical device or medication. Adding to that, how your quality processes are going, or not going, and you have a recipe for FDA 483 observations or worse, FDA Warning letters 2021.
How do companies get to this point? What are the differences? How does a company avoid them?I’ve worked with life-science-related companies for eight years now. When I first started in this vertical, I had no idea what these terms meant or their impact. I quickly learned that the FDA published an email indicating which companies had been cited, including names of the executives, location, and details about their citing. This is terrible news, especially for their patients/customers and employees! Think of the ramifications! You do NOT want to be on either of these FDA lists!
FDA 483 Observations (vs) Warning Letter
The difference between a 483 FDA observation and a Warning Letter is as follows….
483 Observation – A notice that indicates potential regulatory problems. The first inspection team issues this.
Warning Letters – An escalation of the previous FDA audit 483 observations. It’s issued from a higher level of an FDA official.
Based on the FDA’s website:“Make sure everything is written down: all procedures, activities, protocols, etc. Avoid a paper-based system as this is hard to track. Simplify SOPs and maintain and update them regularly. Ensure staff are well trained on company procedures and have a sound understanding of manufacturing practices like GMP.”
The FDA has even More details here as well… https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questionsIn my early years of life sciences, I would call and get calls from individuals at companies. Fortunately, we had consultants (and currently do now) who knew how to remediate these scenarios with efficiencies. This would allow the company to get back on track and stay “above board” when meeting compliance.
The simplistic approach is always to have someone monitoring the regulations and compliance expectations and make sure everyone else knows about them. Keeping a Quality manual up to date and making certain employees are trained against them (marketing and sales too) is preventative medicine.
I remember when an Ebola case had broken out again, around 2014. There was a “sales rep” of an essential oil company who had posted on their blog and was telling people verbally that one of their oils “prevented Ebola.” Uh oh! Someone in the FDA caught wind of the blog. Suddenly, the company was given an FDA 483 form. Thanks to One person, it took a good six months or more to iron all of that out.
In a nutshell (inspected by the FDA, of course 😊), set up procedures with documentation that can be easily accessible to everyone, and trained and retrained against regularly. You also need a resident expert or two on staff or on call to keep everyone informed of new changes. For the sake of your patients, customers, and employees, you need to stay ahead of the game and avoid FDA 483s and Warning Letters.
Connect with Compliance Group today at sales@complianceg.com
FAQ's
When is an FDA Form 483 issued?
The FDA Form 483 is issued after the conclusion of an FDA inspection. It is used as evidence of any points where the inspector thinks that non-compliance might exist. The document is based on findings noted during the inspection process. The report is discussed with company representatives prior to finalizing the inspection process. This gives the company an opportunity to learn of any concerns noted on-site.
Does receiving an FDA 483 mean my company is non-compliant?
The receipt of an FDA 483 is not an indication of non-compliance on the part of the company. The report reflects those observations of the investigator and not the final decision of the FDA. The FDA looks at the results of the inspection and reviews a response from the company before a decision on compliance can be reached. However, unresolved observations can result in further enforcement actions.
What makes a Warning Letter more serious than a 483 observation?
A warning letter is stronger due to the fact that it shows significant regulatory violations that have been confirmed by the FDA. It is an issuance done after reviewing inspection findings and responses by the FDA. Warning letters are public and sometimes may lead to enforcement actions if the issues raised are not corrected on time, unlike Form 483 observations.
Are FDA Warning Letters made public?
The FDA typically publishes all warning letters to the public on their website via warning letter databases. This means that anyone, including federal and state regulators, as well as consumers, can view these documents. However, the observations noted in FDA Form 483 are not automatically available to the general public unless they are publicly released following a specific request for their disclosure.
What should a company do after receiving a 483 observation?
After receiving a 483 observation, the manufacturer must first investigate all observations using root cause analysis and implement corrective and preventive actions to eliminate the issues that prompted the FDA observations. The manufacturer must also provide a comprehensive written response to the FDA within the timeframe established in the FDA letter. The response should clearly detail all corrective actions taken as well as the expected completion dates for those actions.
What are common reasons companies receive an FDA 483 or Warning Letter?
The most common reasons that lead to FDA 483 or Warning Letter are poor standard operating procedure, poor documentation practices, inadequate investigations, ineffective CAPA (Corrective and Preventive Action) systems and lack of employee training. Additionally, many manufacturers receive FDA observations or enforcement actions due to problems with data integrity and failure to adhere to pre-established procedures.
Submit the form below, and our expert will reach out to assist you!
